Acnisal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acnisal

What is Acnisal?

Acnisal is a topical cutaneous solution formulated for the treatment of specific skin conditions characterized by excessive scaling or hardening of the skin. It is primarily classified as a keratolytic agent, designed to soften and remove the outermost layer of the skin.

Active Ingredient and Mechanism

The therapeutic effect of Acnisal is derived from its active ingredient, salicylic acid. This substance works by increasing the amount of moisture in the skin and dissolving the intercellular cement that holds skin cells together. This process facilitates the shedding of dead skin cells and prevents the clogging of pores.

Primary Uses

Acnisal is typically utilized for the management of various dermatological concerns, including:

  • Acne Vulgaris: It helps to clear comedones (whiteheads and blackheads) and prevents the formation of new acne lesions by keeping pores clear.
  • Hyperkeratotic Skin Conditions: It is used to treat localized areas of thickened skin, such as those found in psoriasis or chronic eczema.
  • Scaling and Flaking: The solution aids in the removal of surface scales, improving the overall texture and appearance of the affected skin.

Formulation Characteristics

Acnisal is prepared as a liquid solution, often containing an alcohol-based vehicle. This formulation allows for rapid absorption and ensures that the active ingredient remains in contact with the treated area. The clear, colorless nature of the solution makes it suitable for application on visible areas of the body without leaving a residue.

Regulatory References

  1. United States National Library of Medicine (NLM)

What side effects are possible with Acnisal?

Possible Side Effects and Safety Information

The safety profile for Acnisal (topical Salicylic Acid) is divided between anticipated localized skin effects and the possibility of serious systemic absorption. Many local and systemic effects are officially classified with a Frequency Not Known, as incidence rates cannot be precisely estimated from available data.


Adverse Reaction Scope

Classification Description
Common Skin Reactions Localized skin irritation, stinging, excessive erythema (redness), drying, and scaling or peeling are the expected non-serious effects documented in regulatory labeling.
System-Organ Class Potential systemic effects resulting from excessive absorption are grouped under Skin and Subcutaneous Tissue Disorders (for local allergy/irritation) and Nervous System or Ear and Labyrinth Disorders for symptoms associated with systemic toxicity.
Serious Adverse Reactions The primary serious systemic risk is Salicylism, which is systemic salicylate poisoning. Additionally, regulatory documents note the risk of Reye's Syndrome when salicylates are used in children or teenagers with specific viral infections.

Safety Constraints and Special Populations

Safety notes explicitly address limitations in use based on population and condition:

  • Exposure Patterns: The risk of Salicylism is specifically linked to prolonged or excessive use over large body surface areas, particularly if the skin is broken or inflamed. Local irritation may be more noticeable at the start of treatment.
  • Contraindications: Use is restricted in patients with diabetes or impaired blood circulation. It must not be applied to inflamed, infected, or irritated skin or specific anatomical sites like the eyes or mucous membranes.
  • Special Populations: Caution is required when using the solution in children and adolescents due to increased susceptibility to systemic absorption. Safety is not established for pregnant or lactating women.

The official safety information highlights a clear distinction between anticipated local effects and the potentially serious, yet exposure-dependent, risk of systemic toxicity.

Overdose and Emergency Response

Overdose: Acnisal (Salicylic Acid) and when to seek help

Overdose from Acnisal, a topical Salicylic Acid product, may occur through excessive use over large body areas, prolonged application, or accidental ingestion, leading to systemic toxicity known as Salicylism.

Documented Overdose Manifestations

Regulatory documents identify Salicylism by the presence of specific signs:

  • Central and Auditory Systems: Tinnitus (ringing in the ears), hearing loss, dizziness, lethargy, confusion, and headache.
  • Systemic Effects: Nausea, vomiting, diarrhea, and hyperpnea (abnormally rapid or deep breathing).

Required Emergency Actions

If Salicylism is suspected or if the product is swallowed, use of Acnisal must be immediately discontinued.

Urgent medical attention is required for the onset of any of the documented signs of toxicity, or for any accidental ingestion. Severe Salicylate Poisoning is a medical emergency that can lead to severe outcomes, including respiratory failure, cerebral edema, and seizures.

Management, as described in official labeling, is supportive and may involve methods to enhance elimination, such as intravenous fluid administration, urinary alkalinization, or, in severe cases, hemodialysis.

Population-Specific Notes

The product is generally not recommended for use in children and teenagers with viral illness (e.g., chickenpox or flu) due to the documented potential risk of Reye's Syndrome.

Therapeutic Uses of Acnisal

What Acnisal Treats: Main Uses and Benefits

Acnisal is commonly used to help with the management of acne. The medicine is generally applied in situations involving certain distressing symptoms, including those associated with episodic or fluctuating manifestations and inflammatory or irritative processes.


Managing Episodic Symptomatic Discomfort

Acnisal is commonly used in clinical scenarios where symptoms related to irritative states appear suddenly or intensify, requiring short-term symptomatic assistance. It helps address symptom clusters that may create noticeable interference with daily comfort, contributing to easing the overall symptom load during acute episodes.

“The medicine is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.”


Support for Fluctuating Symptom Patterns

This medication is applied in addressing conditions marked by periods of heightened symptoms. It is useful in scenarios where symptoms escalate temporarily, and by working to help prevent the development of new lesions, Acnisal may assist with maintaining a sense of stability when symptoms become more noticeable.


Relieving Disruptive Symptom Manifestations

It is relevant when symptom clusters lead to temporary functional strain or discomfort. Acnisal provides supportive relief that helps patients cope more steadily with difficult episodes, especially when symptoms interfere with routine activities.

Quick Fact: Supports Improved Comfort

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics for Acnisal

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population/Condition Regulatory Statement
Contraindicated Hypersensitivity Patients with known salicylate allergy or sensitivity to the formulation.
Comorbidity Patients with impaired blood circulation or diabetes (for higher concentrations).
Pediatric Risk Children or teenagers with influenza (flu) or chickenpox (risk of Reye's syndrome).
Not Recommended Age Use in children under 2 years of age is not recommended.
Reproductive Status Safety is not established during pregnancy or lactation.
Established Use Age Adults and adolescents 12 years of age and older without contraindications.

Official Eligibility Statements

Use is restricted on large body areas, prolonged periods, or on broken/irritated skin to limit systemic absorption. The medicine is contraindicated for application on certain lesions, including moles, birthmarks, and warts on the face or mucous membranes. Use near eyes or mucous membranes must be avoided. Caution is advised for older adults with blood vessel disease, and for patients with severe renal or hepatic impairment when large-area use is unavoidable.

Eligibility Context

Regulatory documents define eligibility through absolute contraindications (allergy, viral illness in children) and use limitations based on patient characteristics and application method, primarily to mitigate the risk of excessive systemic absorption.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Acnisal (Topical Salicylic Acid) is structured around the potential for systemic absorption and its subsequent effects on other drug compounds, as documented in government sources. The official classification restricts co-administration with oral aspirin and other systemic or topical salicylate-containing medications to avoid excessive cumulative systemic exposure and the potential for toxicity (salicylism).

The medicine is officially documented to interact with several systemic medications. Salicylate interferes with normal hemostasis and platelet adhesiveness, increasing the risk of bleeding when co-administered with oral anticoagulants (e.g., Warfarin) or Heparin. Salicylate can also decrease the renal tubular reabsorption of Methotrexate, which may result in increased potential for clinical toxicity from Methotrexate. Furthermore, the pharmacological effects of sulfonylureas and Tolbutamide are officially documented to be potentiated, which may enhance the risk of hypoglycemia.

Interactions that modify exposure include Ammonium Sulfate, which increases plasma salicylate levels, and systemic Corticosteroids, which may decrease them. Use is restricted with occlusive dressings or petrolatum-based ointments as these barriers increase systemic absorption. The label mandates avoidance of concomitant use with other topical peeling agents (e.g., benzoyl peroxide) and the use of the product is prohibited in children or teenagers diagnosed with varicella or influenza due to the risk of Reye's syndrome. The potential for systemic toxicity is heightened in patients with significant renal or hepatic impairment.

Mechanism of Action

How Acnisal Works


Targeted Desmolysis and Follicular Clearing

The mechanism of Acnisal centers on its desmolytic action, which chemically disrupts the structural integrity of the outer skin layer. The active ingredient, Salicylic Acid, lowers the local pH to solubilize the corneodesmosomes and the intercellular cement that binds dead skin cells (corneocytes) together. This targeted dissolution accelerates the shedding process, resulting in the physical clearing of the accumulated keratinous plug from the pilosebaceous unit and the maintenance of follicular flow.

Local Modulation of Inflammatory and Sebaceous Pathways

Beyond its shedding mechanism, the drug is a localized modulator of internal cellular signaling. It works by interfering with the inflammatory signaling cascade through the suppression of key markers like NF-κB and Cyclooxygenase ( COX) enzymes, leading to a reduced synthesis of pro-inflammatory mediators. Simultaneously, it acts as a suppressor of the transcription factor SREBP-1, contributing to a diminished rate of lipid (sebum) production within the sebaceous glands, which functionally modifies the biochemical composition within the follicular unit.

Mechanistic Constraints and Peripheral Specificity

The mechanism is strictly defined by its peripheral specificity, meaning its actions are concentrated entirely on the skin's surface and the follicular canal, with minimal systemic absorption or effect. The mechanistic constraints restrict the desmolytic and anti-inflammatory effects to the peripheral targets, correlating its action to conditions requiring targeted, superficial pathway modulation.

Dosage and Administration Information

The administration of Acnisal 2% w/w Cutaneous Solution is structured around a specific topical washing procedure. The medicine is designated solely for external use on the skin as a wash solution, which must be rinsed off.

Labeled Dosing and Administration

The standard regimen involves applying the solution to the affected area two to three times daily. The usage pattern is consistent across different age groups, including children and the elderly. The frequency of application is not fixed indefinitely but is determined by skin tolerability; the usage schedule should be adjusted if undue local skin irritation develops or increases.

The application is process-based, with the instructions detailing a specific sequence:

Procedural Steps:

  • The cutaneous solution must first be lathered with warm water.
  • The lathered product is then massaged into the skin of the affected area.
  • The area must be immediately and thoroughly rinsed and dried following the application.

Connection to the Overall Use Protocol

The overall use protocol is defined by a daily frequency (two to three times per day) combined with the specific procedural steps of lathering, massaging, and subsequent rinsing. The product's application is entirely topical, and the frequency of use is conditional, permitting a necessary adjustment based on local skin tolerability.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acnisal

Evidence for Use in Mild-to-Moderate Acne Vulgaris

Research has primarily explored the use of Acnisal (salicylic acid) for conditions characterized by mild to moderate acne vulgaris. These studies are generally conducted during periods of increased symptom activity and involve conditions characterized by fluctuating or episodic manifestations. Studies examining symptom intensity have included numerous Randomized Controlled Trials (RCTs). These trials often compared the topical solution to a non-active vehicle solution (a placebo) or to other standard topical treatments that were evaluated in conditions marked by heightened symptoms.

Applied in studies examining patient-reported experiences, research explored changes related to outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states. The primary measurement was related to the change in the count of acne lesions from the start of the study, specifically counting both non-inflammatory lesions (like blocked pores or comedones) and inflammatory lesions (such as pimples). Comparisons against the non-active vehicle solution were evaluated in trials. The evidence contributes to the broader evidence landscape for conditions presenting with cycles of stability and flare-ups.


Long-Term Studies and Follow-Up

The majority of evidence that is used to support regulatory evaluation comes from trials with follow-up durations that were limited, mostly in the short-term range (under three months). This means that long-term effects are not fully established, and there is limited information for long-term outcomes regarding the maintenance of symptom control.


Evidence in Special Populations

Acnisal was evaluated in study populations mainly comprised of healthy adolescents and adults. As such, subgroup findings are uncertain for specific populations, particularly older adults (over 65) or people who have other significant health conditions (comorbidities). The results apply only to the populations studied, meaning the evidence provides limited insight into how outcomes might be measured in people outside of the core trial demographic.


What is Still Uncertain About Acnisal Research

Some systematic reviews have noted that sample sizes were modest in many individual trials, contributing to certainty remaining low for some head-to-head comparisons. The comparative evidence is lacking in some areas. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes. More research is ongoing to better explore comparative evidence and long-term use.

Key Studies & References

  1. Emerging Formulations and Clinical Applications of Topical Salicylic Acid in Acne management - Biosciences Biotechnology Research Asia
  2. Summary of Product Characteristics (SPC) for Acnisal 2% w/w Cutaneous Solution (Health Products Regulatory Authority - HPRA)

Frequently Asked Questions (FAQ)

Common questions about Acnisal (FAQ)


Q: What are the most commonly reported side effects of Acnisal?

According to official product information, the most common non-serious side effects anticipated are localized skin reactions. These effects include irritation, stinging, excessive redness (erythema), drying, and scaling or peeling in the area where the solution is applied.


Q: Is it normal to feel a mild burning sensation when starting Acnisal?

Official safety information notes that mild stinging or a burning sensation is a potential, expected reaction, especially at the start of treatment. If severe or excessive burning occurs, official documentation suggests that the product's use may need to be adjusted or stopped.


Q: What kind of research supports the effectiveness of Acnisal?

The evidence supporting the medicine is based on clinical data, including Randomized Controlled Trials (RCTs). These studies compare the solution to non-active solutions and contribute to the evidence base for its ability to help manage conditions like mild-to-moderate acne.


Q: What are the signs of a serious allergic reaction to Acnisal?

Serious allergic (hypersensitivity) reactions, though rare, have been reported for topical salicylic acid products. Signs may include hives, itching of the face or body, throat tightness, difficulty breathing, or swelling of the eyes, face, lips, or tongue. If these symptoms occur, seeking immediate medical assistance is necessary.


Q: Is Acnisal known to cause dryness or peeling?

Yes, official labeling classifies dryness, scaling, or peeling of the skin as common and expected non-serious skin reactions. This effect is generally consistent with the medicine's keratolytic (shedding) mechanism of action.


Q: What is the purpose of the inactive ingredients in Acnisal?

The active ingredient, Salicylic Acid, is formulated in an Emollient Solution base. This liquid base is designed to help soften the skin while efficiently delivering the active agent for effective action on the skin's surface.


Q: What is the difference between Acnisal cream and Acnisal gel?

Acnisal is only manufactured and classified in one official pharmaceutical form, which is a Cutaneous Solution. This is a topical liquid preparation, and the product is not officially available in a cream or gel format.


Q: Are there any long-term side effects associated with Acnisal use?

The serious risk associated with excessive exposure is a condition called Salicylism (systemic toxicity). This risk is linked to prolonged or excessive use over large body areas, especially for individuals with severe renal or hepatic impairment.


Q: Is Acnisal effective for all types of acne?

Official information indicates that the product's use and effectiveness are established primarily for conditions characterized by mild to moderate acne vulgaris. The evidence base primarily addresses this scope, and information on other, more severe skin conditions is limited.


Q: Why do some people experience initial worsening of symptoms with Acnisal?

While not explicitly termed 'worsening,' safety information notes that local irritation may be more noticeable when first starting treatment. Individual tolerance should guide continued use, as usage frequency may need to be adjusted based on skin reaction.


Q: Do studies show Acnisal is more effective than placebo?

Evidence is supported by clinical trials, including randomized studies comparing the solution to a non-active vehicle solution (placebo). These trials contribute to the evidence supporting the active ingredient, Salicylic Acid, as an effective option for its intended use.


Q: Are there generic versions of Acnisal available?

The active ingredient in Acnisal is Salicylic Acid (INN), which is the non-proprietary chemical name. Generic preparations containing topical salicylic acid are widely available, though the formulation and concentration of the full product may vary.


Q: Does Acnisal have systemic effects, or is it purely topical?

The medicine’s actions are defined by their peripheral specificity, meaning they are primarily concentrated on the skin's surface. Systemic absorption is minimal, though the risk of systemic effects (Salicylism) increases with excessive or prolonged application over large areas.


Q: Can people with sensitive skin generally tolerate Acnisal?

Official guidance notes that the frequency of use should be adjusted if undue local skin irritation develops or increases. This indicates that the use of Acnisal is conditional on individual skin tolerability and reaction.


Q: Does using more Acnisal make it work faster?

The use protocol specifies applying the solution a set number of times daily. Regulatory information does not suggest that increasing the application frequency beyond this range will speed up results, and excessive use is associated with an increased risk of side effects.


Q: Are there any known drug interactions with birth control pills and Acnisal?

Regulatory documents list specific systemic drug interactions, such as with oral anticoagulants and Methotrexate. However, hormonal contraceptives (birth control pills) are not typically highlighted as an interaction in the safety information for this topical product.


Q: What is the recommended cleaning routine before applying Acnisal?

The application procedure itself involves a cleansing step: the solution must first be lathered with warm water, massaged into the affected area, and then immediately and thoroughly rinsed and dried. No specific pre-application cleaning routine is mandated beyond this procedural step.

How should Acnisal be stored and disposed of?

Official Storage and Disposal Instructions

Acnisal Cutaneous Solution must be stored and handled according to regulatory requirements to maintain product stability and safety.

Domain Official Requirement
Temperature & Environment Store below 25 C (room temperature), protected from light, moisture, and excess heat.
Handling Prohibition Do not refrigerate or freeze. Keep away from heat and open flame as the solution is flammable.
Stability & Packaging Keep the container tightly closed and in its original bottle. Discard the product 3 months after opening.
Safety & Access Must be stored out of the sight and reach of children.
Disposal Rules Dispose of according to local/national regulations. Do not allow the solution into any sewer or body of water; it must be discarded as non-flushable waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acnisal found in:

A-Z Index: